The Wastage Question: Where Policy Stops and Risk Begins

Wastage has become one of the least defined areas in wound care, even as scrutiny around it continues to increase.

The concept itself is straightforward. Not every graft can be perfectly matched to a wound, and some portion may go unused. What has changed is how those decisions are being evaluated. Expectations have shifted, but the rules governing those expectations have not kept pace.

That gap is where the risk is now. It’s a set of decisions that no longer have a clear reference point. No longer a single question. Now, it’s much more complicated.

Surface area is part of the equation, but wounds are not uniform. Irregular shape, depth, and progression over time all influence what is actually required to treat the patient.

At the same time, the inputs around those decisions are not aligned. Manufacturers offer fixed sizes that do not always reflect how wounds present in practice. Policy language does not fully address how those products are expected to be used. Historical precedent offers limited direction in an audit environment that has become more active and more detailed.

The result is a disconnect between policy and practice.

What This Looks Like in Practice

One of the clearest shifts is in how inventory is managed.

Consignment has become a practical necessity. Physicians cannot reliably predict how a wound will respond week to week, which means the appropriate graft size cannot always be determined in advance. Multiple sizes need to be at the point of care to ensure treatment decisions can be made based on the wound, not on what’s on hand.

That introduces a different level of operational complexity. Inventory must be tracked more closely and product selection has to be documented with greater precision. The rationale behind sizing decisions becomes part of the record, not just the outcome.

At the same time, many of the support structures that previously helped manage this process have atrophied. Field presence has decreased. Communication has slowed. More of the coordination now sits inside the practice.

Where the Risk Lives and What Comes Next

The problem arises when existing policy lacks enough clarity around how it will be applied under the current audit environment. Areas that were not historically a primary focus of enforcement are now examined more closely, leaving providers to make sizing decisions without much certainty of how their decisions will be judged months later.

That uncertainty carries into care. When expectations are unclear, treatment and sizing decisions are influenced as much by perceived defensibility as by clinical judgment. Documentation also takes on greater weight, because the provider is left carrying more of the burden when interpretation becomes part of the review process.

Wastage is one example of a broader gap between policy, product design, and real-world execution. More defined expectations will likely come, but they tend to follow enforcement rather than lead it. Until then, physicians need to be deliberate in how cases are built, how sizing decisions are documented, and how product selection aligns with both clinical need and audit reality.

Bionavix helps practices work through this intersection in real time—bringing clinical, operational, and documentation considerations into better alignment before a case becomes a problem later.

As expectations continue to tighten, providers who approach this environment with greater discipline and clearer strategy will be in a stronger position. Reach out to us if a free consultation might provide the clarity you’re needing on a particular case or situation.